Preliminary study on the immunogenicity of a newly developed GCC Tdap vaccine and its protection efficacy against Bordetella pertussis in a murine intranasal challenge model.
- Author:
Seung Beom HAN
1
;
Kyu Ri KANG
;
Dong Ho HUH
;
Hee Chul LEE
;
Soo Young LEE
;
Jong Hyun KIM
;
Jae Kyun HUR
;
Jin Han KANG
Author Information
- Publication Type:Original Article
- Keywords: Diphtheria-tetanus-acellular pertussis vaccine; Immunogenicity; Efficacy; Mice; Republic of Korea
- MeSH: Adolescent; Adult; Animals; Bacteria; Bordetella pertussis*; Hemagglutinins; Humans; Mice; Pertussis Toxin; Republic of Korea; Spleen; Vaccination; Vaccines; Whooping Cough
- From:Clinical and Experimental Vaccine Research 2015;4(1):75-82
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Active reduced dose tetanus-diphtheria-acellular pertussis (Tdap) vaccination for adolescents and adults is necessary because waning immunity after primary diphtheria-tetanus-pertussis vaccination is related to the recent emergence of pertussis. This study was conducted to compare the immunogenicity and protection efficacy against Bordetella pertussis between a new GCC Tdap vaccine and a commercially available Tdap vaccine in a murine model. MATERIALS AND METHODS: BALB/c mice were immunized with two doses of diphtheria-tetanus-acellular pertussis (DTaP) vaccine for priming and a subsequent Tdap booster vaccination. According to the type of booster vaccine, mice were divided into four groups: commercially available Tdap vaccine in group 1 and GCC Tdap vaccines of different combinations of pertussis antigens in groups 2 to 4. Humoral and cell-mediated immune responses and protection efficacy using a murine intranasal challenge model after booster vaccination were compared among the four groups. RESULTS: Every group showed significant increases in antibody titers against pertussis antigens such as pertussis toxin, filamentous hemagglutinin, and pertactin after booster vaccination. Spleen cells showed both Th1 and Th2 cell-mediated immune responses stimulated by pertussis antigens in all groups without any significant difference. In the intranasal B. pertussis infection model, bacteria were eradicated in all groups five days after challenge infection. CONCLUSION: This preliminary study did not show significantly different immunogenicity or protection efficacy of the new GCC Tdap vaccines compared to the commercially available Tdap vaccine, although a more extensive study is necessary to assess the differing efficacies of the new GCC Tdap vaccines.
